← Home
This Week in Startups · July 22, 2026 · 1h 12m

Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315

Bilal Kharouni, Jason Calacanis

French ex-martial artist Bilal Kharouni discusses why his longevity startup Ekei Labs chose to raise capital and build in Okinawa rather than Silicon Valley. The episode explores how a $200K raise in Japan can outpace a $2M raise in San Francisco, the strategic advantage of building in a Blue Zone, and why proprietary biological data is the real moat for longevity AI. Jason also dives into product-market fit, the decision to kill a profitable side business for focus, Japan's fast-track regulatory pathways for regenerative medicine, and the ceiling on consumer longevity gadgets.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Curious

•
Proprietary Biological Data as the Real Moat for AI in Longevity
In biological AI, the model itself is commoditizing rapidly; the defensible moat is proprietary data—longitudinal aging data, genetic sequencing, and biomarker records that competitors cannot access.
ClaudeChatGPTGemini
•
Japan's Fast-Track Regulatory Pathway for Regenerative Medicine
Japan has created an expedited regulatory approval process for regenerative medicine and biological therapies, allowing companies to reach market faster than FDA-regulated pathways in the United States.
ClaudeChatGPTGemini

Highlights

•
Capital Efficiency: $200K in Japan Outbuilds $2M in San Francisco
A $200,000 raise in Japan can accomplish more product development and market progress than a $2 million raise in Silicon Valley due to lower operational costs, reduced hiring pressure, and different investor timelines.
ClaudeChatGPTGemini

Editorial

•
Blue Zone as Strategic Headquarters for Longevity Research
Building a longevity startup in Okinawa, a world-recognized Blue Zone, provides direct access to the longest-living populations and embedded research infrastructure.
ClaudeChatGPTGemini
•
Killing Profitable Side Business to Maintain Focus
Ekei Labs deliberately shut down a growing, profitable side business to maintain singular focus on the core longevity mission.
ClaudeChatGPTGemini
•
Consumer Longevity Gadgets Have Hit Market Saturation
Wearables and consumer-facing longevity technology like fitness trackers and biometric devices have maxed out their addressable market and efficacy gains.
ClaudeChatGPTGemini

References

■
Blue Zones: Lessons for Living Longer From the People Who've Lived the Longest — Dan Buettner (2008) — Framework for understanding regions with exceptional longevity and healthy aging

Misc

✧Bilal is a former martial artist who pivoted to longevity biotech
✧Ekei Labs killed a growing side business to maintain singular focus on longevity
✧Japan's regulatory environment accelerates regenerative medicine approval compared to US FDA
✧Okinawa as strategic headquarters: direct access to Blue Zone data, local research institutions (OIST), and longer lifespans for empirical testing
✧Japanese PM Takaichi sleeps 2-4 hours nightly—mentioned as cultural context for Japanese work ethic and health optimization
Was this useful?